| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.09 | 0.3 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | -0.033 | 0.3 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.031 | 0.3 |